viral vaccines

Summary

Summary: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.

Top Publications

  1. ncbi Virology, epidemiology, pathogenesis, and control of enterovirus 71
    Tom Solomon
    Brain Infections Group, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
    Lancet Infect Dis 10:778-90. 2010
  2. pmc Foot-and-mouth disease
    Marvin J Grubman
    Plum Island Animal Disease Center, USDA, Agricultural Research Service, North Atlantic Area, Greenport, New York 11944, USA
    Clin Microbiol Rev 17:465-93. 2004
  3. ncbi Identification and characterization of a cross-neutralization epitope of Enterovirus 71
    Chia Chyi Liu
    Vaccine R and D Center, National Health Research Institutes, Zhunan Town, Miaoli County 350, Taiwan
    Vaccine 29:4362-72. 2011
  4. ncbi Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
    Martin F Bachmann
    Research, Cytos Biotechnology AG, Wagistrasse 25, 8952 Schlieren Zürich, Switzerland
    Nat Rev Immunol 10:787-96. 2010
  5. pmc Chikungunya virus arthritis in adult wild-type mice
    Joy Gardner
    Queensland Institute of Medical Research, Australian Centre for International and Tropical Health, Brisbane, Australia
    J Virol 84:8021-32. 2010
  6. pmc A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection
    Wataru Akahata
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 16:334-8. 2010
  7. pmc Norovirus vaccine against experimental human Norwalk Virus illness
    Robert L Atmar
    Baylor College of Medicine, Houston, TX 77030, USA
    N Engl J Med 365:2178-87. 2011
  8. pmc A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 185:769-78. 2012
  9. ncbi Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus
    C N Wu
    Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC
    Vaccine 20:895-904. 2001
  10. ncbi Development of enterovirus 71 vaccines
    Min Shi Lee
    Vaccine Research and Development Center, National Health Research Institutes, Taiwan
    Expert Rev Vaccines 9:149-56. 2010

Research Grants

  1. PATHOGENIC CONVERSION OF ATTENUATED SIV VACCINES
    Earl Sawai; Fiscal Year: 2003
  2. Molecular Basis of Flavivirus Neurovirulence
    William Wold; Fiscal Year: 2007
  3. Modulation of host immune defense by Pneumocystis beta-glucans
    EVA MARIA CARMONA PORQUERA; Fiscal Year: 2013
  4. Development of an effective genital herpes vaccine
    William P Halford; Fiscal Year: 2010
  5. Malaria vaccines modified with TLR agonist adjuvant
    Elizabeth H Nardin; Fiscal Year: 2010
  6. ASM Conference on Viral Genome Replication
    Sean P J Whelan; Fiscal Year: 2011
  7. Adjuvant Enhanced Antiviral Immunity
    JEFF C FAIRMAN; Fiscal Year: 2011
  8. Skin Defense by Antimicrobial Peptides
    Richard L Gallo; Fiscal Year: 2012
  9. Novel dominant-negative HSV-2 recombinant viral vaccines
    Feng Yao; Fiscal Year: 2011
  10. Pathogenesis of Virus-Induced Acute Otitis Media
    Tasnee Chonmaitree; Fiscal Year: 2013

Detail Information

Publications409 found, 100 shown here

  1. ncbi Virology, epidemiology, pathogenesis, and control of enterovirus 71
    Tom Solomon
    Brain Infections Group, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
    Lancet Infect Dis 10:778-90. 2010
    ..Vaccines being developed include inactivated whole-virus, live attenuated, subviral particle, and DNA vaccines...
  2. pmc Foot-and-mouth disease
    Marvin J Grubman
    Plum Island Animal Disease Center, USDA, Agricultural Research Service, North Atlantic Area, Greenport, New York 11944, USA
    Clin Microbiol Rev 17:465-93. 2004
    ....
  3. ncbi Identification and characterization of a cross-neutralization epitope of Enterovirus 71
    Chia Chyi Liu
    Vaccine R and D Center, National Health Research Institutes, Zhunan Town, Miaoli County 350, Taiwan
    Vaccine 29:4362-72. 2011
    ..Thus, VP2-28 could be used as the surrogate biomarker in the potency testing of candidate EV71 vaccines...
  4. ncbi Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
    Martin F Bachmann
    Research, Cytos Biotechnology AG, Wagistrasse 25, 8952 Schlieren Zürich, Switzerland
    Nat Rev Immunol 10:787-96. 2010
    ..In this Review, we discuss the approaches currently being used to optimize the delivery of antigens and enhance vaccine efficacy...
  5. pmc Chikungunya virus arthritis in adult wild-type mice
    Joy Gardner
    Queensland Institute of Medical Research, Australian Centre for International and Tropical Health, Brisbane, Australia
    J Virol 84:8021-32. 2010
    ..This new mouse model of chikungunya virus disease thus provides insights into pathogenesis and a simple and convenient system to test potential new interventions...
  6. pmc A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection
    Wataru Akahata
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 16:334-8. 2010
    ..Immunization with alphavirus VLP vaccines represents a strategy to contain the spread of CHIKV and related pathogenic viruses in humans...
  7. pmc Norovirus vaccine against experimental human Norwalk Virus illness
    Robert L Atmar
    Baylor College of Medicine, Houston, TX 77030, USA
    N Engl J Med 365:2178-87. 2011
    ..Noroviruses cause epidemic and sporadic acute gastroenteritis. No vaccine is available to prevent norovirus illness or infection...
  8. pmc A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 185:769-78. 2012
    ..Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control...
  9. ncbi Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus
    C N Wu
    Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC
    Vaccine 20:895-904. 2001
    ..Our data indicated that inactivated virus is the choice of vaccine preparation capable of fulfilling the demand for effective control, and that VP1 subunit vaccines remain promising vaccine strategies that require further refinement...
  10. ncbi Development of enterovirus 71 vaccines
    Min Shi Lee
    Vaccine Research and Development Center, National Health Research Institutes, Taiwan
    Expert Rev Vaccines 9:149-56. 2010
    ....
  11. pmc West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays
    B S Davis
    Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services, Fort Collins, Colorado 80522, USA
    J Virol 75:4040-7. 2001
    ..This recombinant antigen has great potential to become the antigen of choice and will facilitate the standardization of reagents and implementation of WN virus surveillance in the United States and elsewhere...
  12. ncbi Hemorrhagic fever viruses as biological weapons: medical and public health management
    Luciana Borio
    Johns Hopkins Center for Civilian Biodefense Strategies, Johns Hopkins Schools of Medicine and Public Health, 111 Market Pl, Suite 830, Baltimore, MD 21202, USA
    JAMA 287:2391-405. 2002
    ..To develop consensus-based recommendations for measures to be taken by medical and public health professionals if hemorrhagic fever viruses (HFVs) are used as biological weapons against a civilian population...
  13. ncbi Selection and characterization of vaccine strain for Enterovirus 71 vaccine development
    Jui Yuan Chang
    Vaccine R and D Center, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Township, Miaoli County 350, Taiwan
    Vaccine 30:703-11. 2012
    ..Therefore, these results provide valuable information for cell-based EV71 vaccine development...
  14. ncbi Role of neutralizing antibodies in PRRSV protective immunity
    O J Lopez
    Department of Veterinary and Biomedical Sciences, University of Nebraska Lincoln, 141 VBS, East Campus, UNL, Lincoln, NE 68583 0905, USA
    Vet Immunol Immunopathol 102:155-63. 2004
    ..This information should prove central to the design of new generation vaccines against PRRSV...
  15. ncbi Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccinology
    Tjeerd G Kimman
    Central Veterinary Institute of Wageningen UR CVI, P O Box 65, 8200 AB Lelystad, The Netherlands
    Vaccine 27:3704-18. 2009
    ....
  16. ncbi Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice
    C K Yu
    Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC
    J Biomed Sci 7:523-8. 2000
    ..Pups from hyperimmune dams were resistant to EV71 challenge. Additionally, maternal immunization with a formalin-inactivated whole-virus vaccine prolonged the survival of pups after EV71 lethal challenge...
  17. ncbi Virus-like particles in vaccine development
    António Roldão
    Instituto de Tecnologia Qu and x00ED mica e Biol and x00F3 gica Universidade Nova de Lisboa, Apartado 127, P 2781 901, Oeiras, Portugal
    Expert Rev Vaccines 9:1149-76. 2010
    ..Successful VLP-based vaccine blockbusters are briefly presented concomitantly with the latest results from clinical trials and the recent developments in chimeric VLP-based technology for either therapeutic or prophylactic vaccination...
  18. pmc Study of the integrated immune response induced by an inactivated EV71 vaccine
    Longding Liu
    Institute of Medical Biology, Chinese Academy of Medicine Science, Peking Union Medical College, Kunming, People s Republic of China
    PLoS ONE 8:e54451. 2013
    ..Furthermore, the immune response was not accompanied by the development of a remarkable inflammatory response...
  19. pmc Production of EV71 vaccine candidates
    Pele Chong
    Vaccine R and D Center, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan
    Hum Vaccin Immunother 8:1775-83. 2012
    ..This review also demonstrates the opportunities and challenges that the Asian vaccine industry faces today. ..
  20. ncbi Immunogenic and protective effects of an oral DNA vaccine against infectious pancreatic necrosis virus in fish
    Ana I de Las Heras
    Centro de Investigaciones Biologicas, Departamento de Microbiología Molecular y Biología de las Infecciones, C Ramiro de Maeztu 9, 28040 Madrid, Spain
    Fish Shellfish Immunol 28:562-70. 2010
    ..Thus, this study demonstrates the potential of the encapsulation technique for IPNV-DNA vaccine delivery and the relevance of the IPNV-VP2 gene for future plasmid constructs...
  21. ncbi Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial
    Yan Ping Li
    The Center for Disease Control and Prevention of the Guangxi Zhuang Autonomous Region, China
    Vaccine 30:3295-303. 2012
    ..6-15.3), and 27.4 (95% CI, 14.3-52.2) in the 100 U, 200 U, and 400 U vaccine groups, respectively; after two doses, the GMTs were 114.1 (95% CI, 44.5-292.4), 159.5 (95% CI, 49.3-515.3), and 509.0 (95% CI, 181.3-1429.1), respectively...
  22. pmc The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain
    Cesar G Albarino
    Centers for Disease Control and Prevention, MS G14, Atlanta, GA 30329, USA
    J Virol 85:10404-8. 2011
    ..This work provides insight into the molecular mechanisms of attenuation of the only arenavirus vaccine currently available...
  23. pmc Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice
    James F Papin
    International Laboratory of Molecular Biology for Tropical Disease Agents, School of Veterinary Medicine, University of California, Davis, CA 95616, USA
    Proc Natl Acad Sci U S A 108:14926-31. 2011
    ..Furthermore, both vaccines induced protective levels of antibody titers in vaccinated mice and baboons. Mice were protected from lethal RVFV challenge. Thus, we have developed two safe and efficacious recombinant vaccines for RVF...
  24. ncbi Porcine circovirus type 2 associated disease: update on current terminology, clinical manifestations, pathogenesis, diagnosis, and intervention strategies
    Tanja Opriessnig
    Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA
    J Vet Diagn Invest 19:591-615. 2007
    ..This article is intended to discuss the most common disease manifestations, pathogenesis, diagnostic approaches, and intervention strategies associated with PCVAD in North America...
  25. ncbi Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 172:6290-7. 2004
    ..Moreover, these studies suggest that using Ad vectors derived from immunologically distinct serotypes may be an effective and general strategy to overcome the suppressive effects of pre-existing anti-Ad immunity...
  26. pmc Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus
    Karuppiah Muthumani
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Vaccine 26:5128-34. 2008
    ..Taken together, these data support further study of the use of consensus CHIK antigens in a potential vaccine cocktail...
  27. ncbi Tick-borne encephalitis virus - a review of an emerging zoonosis
    K L Mansfield
    Rabies and Wildlife Zoonoses Group, Veterinary Laboratories Agency, Surrey, UK
    J Gen Virol 90:1781-94. 2009
    ..We also discuss the factors which may have influenced an apparent increase in the number of reported human cases each year, despite the availability of effective vaccines...
  28. ncbi Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection
    Emily Jane Bek
    Infectious Diseases and Immunology, The University of Sydney, Australia
    Vaccine 29:4829-38. 2011
    ..Immunised mice developed a neutralising antibody response to both the immunising C4 strain and to the mouse-adapted strain. Mice born to immunised dams showed significantly less myositis and reduced viral loads in tissues...
  29. pmc An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys
    Minetaro Arita
    Department of Virology II, National Institute of Infectious Diseases, 4 7 1 Gakuen, Musashimurayama shi, Tokyo 208 0011, Japan
    J Virol 81:9386-95. 2007
    ..In the CNS, EV71(S1-3') was isolated only from the spinal cord. These results indicate that EV71(S1-3') acts as an effective antigen, although this attenuated strain was still neurotropic when inoculated via the intravenous route...
  30. ncbi Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys
    Chenghong Dong
    Institute of Medical Biology, Chinese Academy of Medicine Science, Kunming 650118, PR China
    Vaccine 29:6269-75. 2011
    ....
  31. ncbi Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18
    Diana V Pastrana
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892 4263, USA
    Virology 321:205-16. 2004
    ..The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies...
  32. pmc Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism
    Kenneth Plante
    Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
    PLoS Pathog 7:e1002142. 2011
    ..Furthermore, it is incapable of replicating in mosquito cells or infecting mosquitoes in vivo. This IRES-based attenuation platform technology may be useful for the predictable attenuation of any alphavirus...
  33. ncbi Prophylaxis and therapy for Chikungunya virus infection
    Thérèse Couderc
    Groupe Microorganismes et Barrières de l Hôte and Unité Interactions Moléculaires Flavivirus Hôtes, Centre National de Référence des Arbovirus, Institut Pasteur, INSERM, Avenir U604, and Universite Paris Descartes, Hopital Necker Enfants Malades, Paris, France
    J Infect Dis 200:516-23. 2009
    ....
  34. ncbi Field effectiveness of vaccination against tick-borne encephalitis
    Franz X Heinz
    Institute of Virology, Medical University of Vienna, Kinderspitalgasse 15, AT 1095 Vienna, Austria
    Vaccine 25:7559-67. 2007
    ..Our data confirm the excellent performance of TBE vaccine under field conditions and provide evidence that, in Austria, about 2800 cases were prevented by vaccination in the years 2000-2006...
  35. ncbi Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge
    Yao Chi Chung
    Department of Chemical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan
    Vaccine 26:1855-62. 2008
    ..These data collectively indicate the importance of the preservation of VLP structure and implicate the potential of VLP as a vaccine to prevent EV71 infection...
  36. pmc Chimeric alphavirus vaccine candidates for chikungunya
    Eryu Wang
    Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555, United States
    Vaccine 26:5030-9. 2008
    ..Vaccinated mice were fully protected against disease and viremia after CHIKV challenge...
  37. ncbi The effect of enterovirus 71 immunization on neuropathogenesis and protein expression profiles in the thalamus of infected rhesus neonates
    Huicheng Chen
    Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, Yunnan 650118, PR China
    Virology 432:417-26. 2012
    ....
  38. ncbi Alloantibodies against MHC class I: a novel mechanism of neonatal pancytopenia linked to vaccination
    Gilles Foucras
    Universite de Toulouse, Institut National Polytechnique de Toulouse, Ecole Nationale Veterinaire de Toulouse, F 31076 Toulouse, France
    J Immunol 187:6564-70. 2011
    ....
  39. ncbi Novel strategies and approaches to develop the next generation of vaccines against porcine reproductive and respiratory syndrome virus (PRRSV)
    Y W Huang
    Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061 0913, USA
    Virus Res 154:141-9. 2010
    ....
  40. pmc Filovirus vaccines
    Steven B Bradfute
    United States Army Medical Research Institute of Infectious Diseases, National Interagency Biodefense Campus Fort Detrick, Frederick, MD, USA
    Hum Vaccin 7:701-11. 2011
    ..Furthermore, the uses of rodent models in vaccine development, as well as correlates of immunity, are discussed...
  41. ncbi Current strategies for subunit and genetic viral veterinary vaccine development
    Alejandro Brun
    Centro de Investigación en Sanidad Animal CISA INIA, Valdeolmos, 28130 Madrid, Spain
    Virus Res 157:1-12. 2011
    ..This paper reviews several antigen production and delivery strategies other than those based on the use of live viral vectors. Genetic and protein subunit vaccines as well as alternative production systems are considered in this review...
  42. pmc Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates
    Ai Hsiang Chou
    Vaccine R and D Center, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan
    PLoS ONE 7:e34834. 2012
    ..Based on the success of inactivated poliovirus vaccine, a prototype chemically inactivated EV71 vaccine candidate has been developed and currently in human phase 1 clinical trial...
  43. ncbi Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71
    Qunying Mao
    National Institute for the Control of Pharmaceutical and Biological Products, Beijing 100050, China
    Arch Virol 157:37-41. 2012
    ..0%-99.8% genome homology of the VP1 regions, but their cross-neutralization capacities varied. These results showed that vaccine strains with good cross-neutralization capacities had the potential to be vaccine strains...
  44. pmc Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins
    Gene G Olinger
    United States Army Medical Research Institute of Infectious Diseases, Division of Virology, 1425 Porter Street, Frederick, MD 21702 5011, USA
    J Virol 79:14189-96. 2005
    ....
  45. pmc Progress in filovirus vaccine development: evaluating the potential for clinical use
    Darryl Falzarano
    Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, 903 South 4th Street, Hamilton, MT 59840, USA
    Expert Rev Vaccines 10:63-77. 2011
    ..These results demonstrate that achieving a vaccine that is protective against filoviruses is possible; the challenge now is to prove its safety and efficacy in order to obtain a vaccine that is ready for human use...
  46. ncbi The Xs and Y of immune responses to viral vaccines
    Sabra L Klein
    W Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Lancet Infect Dis 10:338-49. 2010
    ..clinical data illustrate that men and women differ in their innate, humoral, and cell-mediated responses to viral vaccines. Sex affects the frequency and severity of adverse effects of vaccination, including fever, pain, and ..
  47. ncbi EV71: an emerging infectious disease vaccine target in the Far East?
    Juan Xu
    Department of Microbiology and Immunology, Nanjing Medical University, Nanjing 210030, China
    Vaccine 28:3516-21. 2010
    ....
  48. ncbi Virus-like particles: passport to immune recognition
    Elizabeth V L Grgacic
    Macfarlane Burnet Institute for Medical Research and Public Health, 85 Commercial Road, Melbourne 3004, Australia
    Methods 40:60-5. 2006
    ..This review outlines some of the advantages, disadvantages, and technical considerations for the use of a wide range of VLP systems in vaccine development...
  49. ncbi Assessment of the efficacy of commercial porcine reproductive and respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic response, frequency of gamma-IFN-producing cells and virological parameters of protection upon challenge
    Federico A Zuckermann
    Department of Pathobiology, College of Veterinary Medicine, University of Illinois, USA
    Vet Microbiol 123:69-85. 2007
    ..In the case of the modified live vaccine, the protection exhibited did not appear to be based on humoral but rather on cell-mediated immunity...
  50. pmc Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease
    Jodi K Craigo
    Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Vaccine 28:8095-104. 2010
    ..We demonstrate here that the attenuated strain progressively evolved during the six-month pre-challenge period and that the observed protection from disease was significantly associated with divergence from the original vaccine strain...
  51. pmc Biodegradable nanoparticle-entrapped vaccine induces cross-protective immune response against a virulent heterologous respiratory viral infection in pigs
    Varun Dwivedi
    Food Animal Health Research Program, Ohio Agricultural Research and Development Center, The Ohio State University, Wooster, Ohio, United States
    PLoS ONE 7:e51794. 2012
    ..In summary, we demonstrated the benefits of intranasal delivery of nanoparticle-based viral vaccine in eliciting cross-protective immune response in pigs, a potential large animal model...
  52. ncbi High burden of tick-borne encephalitis in Slovenia--challenge for vaccination policy
    Marta Grgic-Vitek
    National Institute of Public Health, Trubarjeva 2, 1000 Ljubljana, Slovenia
    Vaccine 29:5178-83. 2011
    ....
  53. ncbi Comparison of vaccine efficacy for different antigen delivery systems for infectious pancreatic necrosis virus vaccines in Atlantic salmon (Salmo salar L.) in a cohabitation challenge model
    Hetron M Munang'andu
    Norwegian School of Veterinary Science, Department of Basic Sciences and Aquatic Medicine, Section of Aquatic Medicine and Nutrition, P O Box 8146 Dep, N 0033 Oslo, Norway
    Vaccine 30:4007-16. 2012
    ..Hence, there still remains the challenge of developing highly efficacious vaccines with the ability to eliminate the post challenge carrier state in IPNV vaccinology...
  54. ncbi Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys
    Chenghong Dong
    Institute of Medical Biology, Chinese Academy of Medicine Science, Peking Union Medical College, PR China
    Hum Vaccin 6:1028-37. 2010
    ..The experimentally inactivated vaccine produced using this strain was capable of inducing an immune response and offered protection to rhesus monkeys against future virus attacks...
  55. pmc Rift valley fever: recent insights into pathogenesis and prevention
    Hani Boshra
    Centro de Investigación en Sanidad Animal CISA INIA, Carretera de Valdeolmos El Casar s n, Valdeolmos, Madrid, Spain 28130
    J Virol 85:6098-105. 2011
    ..Progress in understanding the epidemiology of Rift Valley fever has also enabled prediction of potential outbreaks well in advance, thus providing another tool to combat the physical and economic impact of this disease...
  56. ncbi Effect of the vaccination scheme on PregSure® BVD induced alloreactivity and the incidence of Bovine Neonatal Pancytopenia
    Rahel Kasonta
    Paul Ehrlich Institut, Paul Ehrlich Strasse 51 59, D 63225 Langen, Germany
    Vaccine 30:6649-55. 2012
    ....
  57. pmc Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence
    B P Peeters
    Department of Avian Virology, Institute for Animal Science and Health, 8200 AB Lelystad, The Netherlands
    J Virol 73:5001-9. 1999
    ..These results demonstrate that genetically modified NDV can be recovered from cloned cDNA and confirm the supposition that cleavage of the F0 protein is a key determinant in virulence of NDV...
  58. ncbi Effective induction of high-titer antibodies by viral vector vaccines
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Nat Med 14:819-21. 2008
    ..Antibodies induced against a blood-stage malaria antigen by this viral vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falciparum in vitro...
  59. ncbi Virus-like particles as immunogens
    Rob Noad
    Dept of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Trends Microbiol 11:438-44. 2003
    ..VLPs have therefore shown dramatic effectiveness as candidate vaccines. Here, we review the current status of VLPs as vaccines, and discuss the characteristics and problems associated with producing VLPs for different viruses...
  60. ncbi Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: Use in emergency outbreak response
    William T Golde
    Plum Island Animal Disease Center, Foot and Mouth Disease Unit PIADC, ARS, USDA P O Box 848 Greenport, NY 11944, USA
    Vaccine 23:5775-82. 2005
    ..These significant effects at 4 days post vaccination, confirmed in two separate trials, support the value of using currently available vaccines as a first line of defense against foot-and-mouth disease (FMD) outbreaks...
  61. pmc Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
    Cell Host Microbe 5:95-105. 2009
    ..Multistage immunity against malaria can thus be achieved by using viral vectors recombinant for MSP-1...
  62. ncbi Reproductive performance of gilts following vaccination and subsequent heterologous challenge with European strains of porcine reproductive and respiratory syndrome virus
    Mariela Scortti
    Dpto de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, Avda Puerta de Hierro s n, 28040 Madrid, Spain
    Theriogenology 66:1884-93. 2006
    ....
  63. ncbi Attenuation of porcine reproductive and respiratory syndrome virus strain MN184 using chimeric construction with vaccine sequence
    Yue Wang
    Department of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN 55108, USA
    Virology 371:418-29. 2008
    ....
  64. ncbi Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50-90 years
    Birgit Weinberger
    Institute for Biomedical Aging Research, Austrian Academy of Sciences, Rennweg 10, 6020 Innsbruck, Austria
    Vaccine 28:3511-5. 2010
    ..Our results clearly indicate that the responsiveness of the immune system to vaccination is already impaired at the age of 50...
  65. pmc Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus
    Thomas W Geisbert
    Department of Microbiology, National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Virol 83:7296-304. 2009
    ..In conclusion, we developed an immunization scheme based on a single-injection vaccine that protects nonhuman primates against lethal challenge with representative strains of all human pathogenic filovirus species...
  66. pmc Protection of European domestic pigs from virulent African isolates of African swine fever virus by experimental immunisation
    Katherine King
    Institute for Animal Health Pirbright Laboratory, Pirbright, Woking, Surrey GU24 0NF, UK
    Vaccine 29:4593-600. 2011
    ..Cross-protection was correlated with the ability of different ASFV isolates to stimulate immune lymphocytes from the OURT88/3 and OURT88/1 immunised pigs...
  67. pmc Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions
    Christiana Fogg
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Virol 78:10230-7. 2004
    ..Three immunizations with the three-protein combination were necessary and sufficient for complete protection. These studies suggest the feasibility of a multiprotein smallpox vaccine...
  68. pmc Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates
    Thomas W Geisbert
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    J Virol 84:10386-94. 2010
    ....
  69. ncbi Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine
    Sagar U Kapadia
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Virology 340:174-82. 2005
    ..A VSV-vectored SARS vaccine could have significant advantages over other SARS vaccine candidates described to date...
  70. pmc Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP
    Magali E Droniou-Bonzom
    Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, 2011 Zonal Avenue, HMR502, Los Angeles, CA 90033, USA
    J Virol 85:13457-62. 2011
    ..Lastly, we identified an increased dependence of Cd1 GP on human transferrin receptor type 1 (hTfR-1) for entry, which may affect the tropism of the attenuated strain in vivo...
  71. ncbi Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania
    Muhammad Bakari
    Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
    Vaccine 29:8417-28. 2011
    ....
  72. ncbi Coronavirus avian infectious bronchitis virus
    Dave Cavanagh
    Institute for Animal Health, Compton Laboratory, Compton, Newbury, Berkshire RG20 7NN, United Kingdom
    Vet Res 38:281-97. 2007
    ..Experimental vector IB vaccines and genetically manipulated IBVs--with heterologous spike protein genes--have produced promising results, including in the context of in ovo vaccination...
  73. ncbi Cell-mediated immune response and cross-protective efficacy of binary ethylenimine-inactivated bluetongue virus serotype-1 vaccine in sheep
    Channakeshava Sokke Umeshappa
    Center for Animal Disease Research and Diagnosis, Pathology Laboratory, Indian Veterinary Research Institute, Izatnagar 243 122, Bareilly, Uttar Pradesh, India
    Vaccine 28:2522-31. 2010
    ..Collectively, these data suggested that inactivated BTV-1 vaccine induced appreciable CMI and greatly reduced the severity of heterologous BTV-23 infection...
  74. ncbi Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C
    Carmen Elena Gómez
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
    Vaccine 25:1969-92. 2007
    ..These results demonstrate the immunogenic potential of MVA-C and NYVAC-C as novel vaccine candidates against clade C of HIV-1...
  75. ncbi Replication-defective viruses as vaccines and vaccine vectors
    Tim Dudek
    Program in Biological Sciences and Public Health, Harvard School of Public Health, Boston, MA 02115, USA
    Virology 344:230-9. 2006
    ..As vaccines, these mutant viruses have advantages of both classical types of viral vaccines in being as safe as inactivated virus but expressing viral antigens inside infected cells so that MHC class I ..
  76. pmc T cell-dependence of Lassa fever pathogenesis
    Lukas Flatz
    Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
    PLoS Pathog 6:e1000836. 2010
    ..The possibility of T cell-driven enhancement and immunopathogenesis should be given consideration in future LF vaccine development...
  77. ncbi The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution
    R Acharya
    Laboratory of Molecular Biophysics, Oxford, UK
    Nature 337:709-16. 1989
    ..The most immunogenic portion of the capsid, which acts as a potent peptide vaccine, forms a disordered protrusion on the virus surface...
  78. ncbi Combined peptides of human enterovirus 71 protect against virus infection in mice
    Jiang Ning Liu
    Key Laboratory of Human Diseases Comparative Medicine, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences CAMS and Comparative Medicine Centre, Peking Union Medical Collage PUMC, Beijing 100021, China ljn
    Vaccine 28:7444-51. 2010
    ..Our results suggested that Vac6 could have potential clinical value against EV71 epidemics caused mainly by C4 strains in the mainland of China...
  79. ncbi High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture
    Chia Chyi Liu
    Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan
    Vaccine 25:19-24. 2007
    ..Therefore, serum-free microcarrier culture is a valuable process for developing inactivated EV71 vaccines...
  80. pmc Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses
    Jinying Ge
    National Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, CAAS, 427 Maduan Street, Harbin 150001, People s Republic of China
    J Virol 81:150-8. 2007
    ..The recombinant NDV vaccine may also have potential use in high-risk human individuals to control the pandemic spread of lethal avian influenza...
  81. pmc The detection of antibodies against peste des petits ruminants virus in cattle, sheep and goats and the possible implications to rinderpest control programmes
    J Anderson
    ARFC Institute for Animal Health, Pirbright Laboratory, Woking, Surrey, UK
    Epidemiol Infect 112:225-31. 1994
    ....
  82. ncbi Studies of genetically defined chimeras of a European type A virus and a South African Territories type 2 virus reveal growth determinants for foot-and-mouth disease virus
    H G van Rensburg
    Onderstepoort Veterinary Institute, Exotic Diseases Division, Private Bag X05, Onderstepoort 0110, South Africa
    J Gen Virol 85:61-8. 2004
    ..Evaluation of the growth of various SAT2/A12 chimeras created during the derivation of SAT2 infectious cDNA suggested incompatibilities between the non-structural proteins of ZIM/7/83 and the 5' UTR of A(12)...
  83. pmc Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections
    Dana L Swenson
    U S Army Medical Research Institute of Infectious Diseases, 1425 Porter St, Fort Detrick, Frederick, Maryland 21702 5011, USA
    Clin Vaccine Immunol 15:460-7. 2008
    ..This study indicates the feasibility of vaccination against all current filovirus threats in the event of natural hemorrhagic fever outbreak or biological attack...
  84. ncbi Adenoviruses as vaccine vectors
    Nia Tatsis
    The Wistar Institute, University of Pennsylvania, Philadelphia, PA 19104, USA
    Mol Ther 10:616-29. 2004
    ..This field is growing at an exciting and rapid pace, thus we have limited our scope to the use of adenoviral vectors as vaccines against viral pathogens...
  85. ncbi Effective synthetic peptide vaccine for foot-and-mouth disease in swine
    Chang Yi Wang
    United Biomedical Inc, 25 Davids Drive, Hauppauge, NY 11788, USA
    Vaccine 20:2603-10. 2002
    ..5 microg, and a mild adjuvant that caused no lesions. A safe chemically-defined product would have considerable advantages for vaccination against FMD...
  86. pmc Dengue and dengue hemorrhagic fever
    D J Gubler
    Division of Vector Borne Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado 80522, USA
    Clin Microbiol Rev 11:480-96. 1998
    ..A major challenge for public health officials in all tropical areas of the world is to develop and implement sustainable prevention and control programs that will reverse the trend of emergent dengue hemorrhagic fever...
  87. ncbi A comparative review on European-farmed finfish RNA viruses and their vaccines
    E Gomez-Casado
    Instituto Nacional Investigaciones Agrarias, Dpto Biotecnología, INIA, 28040 Madrid, Spain
    Vaccine 29:2657-71. 2011
    ....
  88. ncbi Immune responses of pigs inoculated with a recombinant fowlpox virus coexpressing GP5/GP3 of porcine reproductive and respiratory syndrome virus and swine IL-18
    Guoshun Shen
    Genetic Engineering Laboratory, Academy of Military Medical Sciences, Changchun 130062, PR China
    Vaccine 25:4193-202. 2007
    ..The results demonstrated the potential use of a fowlpox virus-based recombinant vaccine in the control and prevention of PRRSV infections...
  89. pmc Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep
    Brian H Bird
    Viral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road, MS G 14, Atlanta, GA 30329, USA
    J Virol 85:12901-9. 2011
    ..As expected, all 3 sham-vaccinated controls experienced viremia, fetal death, and abortion postchallenge. These results demonstrate that the ΔNSs-ΔNSm rRVFV vaccine is safe and nonteratogenic and confers high-level protection in sheep...
  90. ncbi Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep
    Baptiste Dungu
    Onderstepoort Biological Products Ltd, Private Bag X07, Onderstepoort 0110, South Africa
    Vaccine 28:4581-7. 2010
    ..A vaccine dose-response effect was also observed...
  91. pmc Rift valley fever vaccines
    Tetsuro Ikegami
    Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555 0438, USA
    Vaccine 27:D69-72. 2009
    ..Effective vaccination of both humans and ruminants is the best approach to control Rift Valley fever. This article summarizes the development of inactivated RVFV vaccine, live attenuated vaccine, and other new generation vaccines...
  92. ncbi Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep
    Michael Eschbaumer
    Institute of Diagnostic Virology, Friedrich Loeffler Institut, Südufer 10, 17493 Greifswald Insel Riems, Germany
    Vaccine 27:4169-75. 2009
    ..Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected...
  93. pmc Nipah virus: vaccination and passive protection studies in a hamster model
    V Guillaume
    INSERM Unite 404 UBIVE, Institut Pasteur, CERVI, IFR 128, Lyon, France
    J Virol 78:834-40. 2004
    ....
  94. ncbi Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara
    Caroline Staib
    GSF Institute of Molecular Virology and Institute of Virology, Technical University of Munich, Trogerstrasse 4b, 81675 Munchen, Germany
    J Gen Virol 86:1997-2006. 2005
    ..These data suggest that deletion of the viral IL1betaR gene may be considered a relevant approach to amplify the virus-specific CD8+ memory T-cell response and duration of protective immunity obtained after MVA vaccination...
  95. ncbi Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71
    Cheng Hsun Chiu
    Department of Pediatrics, Chang Gung Children s Hospital, Chang Gung University College of Medicine, Kweishan, Taoyuan 333, Taiwan
    Microbes Infect 8:1671-8. 2006
    ..Our data indicated that Salmonella-based VP1 subunit vaccines are a promising vaccine strategy in the prevention of EV71 infection...
  96. ncbi Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine
    John C Morrill
    Applied Research Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA
    J Infect Dis 204:617-25. 2011
    ..A single inoculation of the RVF MP-12 live attenuated vaccine by the aerosol or intranasal route may provide an alternative route of protective immunization to RVFV in addition to conventional intramuscular injection...
  97. ncbi Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats
    E Breard
    Anses, UMR Virology 1161, Laboratoire de Sante Animale, Maisons Alfort, France
    Vaccine 29:2495-502. 2011
    ..Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines...
  98. pmc Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever
    Luis M Branco
    Tulane University Health Sciences Center, New Orleans, LA, USA
    Virol J 7:279. 2010
    ..To this end, we have employed efficient mammalian expression systems to generate a Lassa virus (LASV)-like particle (VLP)-based modular vaccine platform...
  99. pmc Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model
    Marco A Goicochea
    Institute of Human Virology, University of Maryland, School of Medicine, Baltimore, MD 21201, United States
    Vaccine 30:1445-52. 2012
    ..The CBA/J-ML29 model can be useful immunological tool for the preliminary evaluation of immunogenicity and efficacy of vaccine candidates against LASV outside of BSL-4 containment facilities...
  100. pmc An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles
    Lissette S Velasquez
    Center for Infectious Diseases and Vaccinology, Biodesign Institute, Arizona State University, Tempe, AZ 85287 5001, USA
    Clin Vaccine Immunol 17:1850-8. 2010
    ..g., respiratory and reproductive tracts) are desired...
  101. pmc Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo
    Susan L Pichla-Gollon
    Division of Infectious Diseases, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Virol 83:5567-73. 2009
    ..The results thus suggest that in vitro neutralization assays may not reliably predict the effects of virus-specific antibodies on adenovirus vectors in vivo...

Research Grants65

  1. PATHOGENIC CONVERSION OF ATTENUATED SIV VACCINES
    Earl Sawai; Fiscal Year: 2003
    ..well as replication-competent SIV vectors expressing cytokines in place of nef, were tested as live-attenuated viral vaccines in juveniles and adults...
  2. Molecular Basis of Flavivirus Neurovirulence
    William Wold; Fiscal Year: 2007
    ..Information from these studies may be used to design and improve live-attenuated viral vaccines for viruses of public health importance, as well as to gain insight into the mechanisms of viral pathogenesis...
  3. Modulation of host immune defense by Pneumocystis beta-glucans
    EVA MARIA CARMONA PORQUERA; Fiscal Year: 2013
    ..proves it potential role as a potent vaccine adjuvant it could also be applied to other fungal, bacterial and viral vaccines, to enhance protection...
  4. Development of an effective genital herpes vaccine
    William P Halford; Fiscal Year: 2010
    ..combined with current knowledge of HSV biology may be applied to derive live, replicating HSV-1 and HSV-2 viral vaccines that are safe and immunogenic...
  5. Malaria vaccines modified with TLR agonist adjuvant
    Elizabeth H Nardin; Fiscal Year: 2010
    ..The techniques used for the design, purification and production of potent TLR agonist modified viral vaccines will be utilized to develop a P...
  6. ASM Conference on Viral Genome Replication
    Sean P J Whelan; Fiscal Year: 2011
    ..b>Viral vaccines have proved effective in controlling many diseases and have resulted in the global eradication of smallpox...
  7. Adjuvant Enhanced Antiviral Immunity
    JEFF C FAIRMAN; Fiscal Year: 2011
    ..is the completion of pre-clinical evaluation and development of the CLDC product for use as an adjuvant in viral vaccines and specifically for influenza...
  8. Skin Defense by Antimicrobial Peptides
    Richard L Gallo; Fiscal Year: 2012
    ..The later impacts the capacity to administer live viral vaccines such as the smallpox vaccine...
  9. Novel dominant-negative HSV-2 recombinant viral vaccines
    Feng Yao; Fiscal Year: 2011
    ..The vaccine efficacy of IL15/gB2-expressing CJ2-gD2 in preventing primary and recurrent HSV-2 genital disease will be evaluated in mouse and guinea pig models of HSV-2 intravaginal infection. ..
  10. Pathogenesis of Virus-Induced Acute Otitis Media
    Tasnee Chonmaitree; Fiscal Year: 2013
    ..implication an will lay the ground work for future design and development of novel strategies such as specific viral vaccines, use of antivirals or antibiotics to prevent URI and/or AOM to reduce the public health burden of these highly ..
  11. Clinical Development of Combination Plague/Smallpox Vaccine
    CHARALAMBOS PARTIDOS; Fiscal Year: 2011
    ..extensive experience with the manufacture, preclinical testing and regulatory submissions for recombinant viral vaccines will speed the progress of this needed product from the bench to the clinic...
  12. Towards a Vaccine for the Common Cold
    THOMAS JAMES SMITH; Fiscal Year: 2010
    Traditional viral vaccines are normally developed by either creating attenuated viral strains for inoculation, such as the Sabine strain of poliovirus, or by injecting the patients with purified viral proteins such as employed in the ..
  13. Burden of RSV and Influenza Virus in Children in Pakistan
    Syed Asad Ali; Fiscal Year: 2012
    ..If a significant burden is confirmed, then a study to use viral vaccines to reduce this burden can be proposed to other funding agencies...
  14. Generation and Function of NK Cell Memory
    Ulrich H von Andrian; Fiscal Year: 2013
    ..It is hoped that the mechanistic insights gained from these highly interactive and synergistic experiments will lead to new, evidence-based and knowledge-driven development strategies for anti-viral vaccines.
  15. Anti-viral immune responses in lymph node
    Ulrich H von Andrian; Fiscal Year: 2012
    ..It is hoped that the mechanistic insights gained from these highly interactive and synergistic experiments will lead to new, evidence-based and knowledge-driven development strategies for anti-viral vaccines.
  16. Evolution &Maintenance of Memory CD8 T Cells
    KATHERINE F LUZURIAGA; Fiscal Year: 2013
    ..specific and cross-reactive CD8+ T cell responses should contribute to the development of new or improved viral vaccines and the development of novel therapies for autoimmune diseases or virus-associated malignancies...
  17. Development of a novel adjuvant for vaccine sparing
    Hao Shen; Fiscal Year: 2013
    ..response and cellular responses to several soluble vaccine candidate antigens, and commercial inactivated viral vaccines, including trivalent-inactivated flu vaccines (TIV)...
  18. Bioengineering protocells for a new class of viral vaccines
    Matteo Porotto; Fiscal Year: 2012
    ..The results will be highly relevant in light of the importance of paramyxoviruses to human health and the potential broad applicability of the bioengineering approach to vaccine development for these and other serious pathogens. ..
  19. Identification of compounds that activate interferon to treat viral infections
    Luis Martinez-Sobrido; Fiscal Year: 2011
    ..These interferon-inducing compounds could be also used as immunomodulators and/or adjuvants for viral vaccines, illustrating their immediate and significant impact on human health...
  20. Elucidation of mechanisms that contribute to antigenic drift of influenza viruses
    SCOTT ERIC HENSLEY; Fiscal Year: 2012
    ..Project Narrative: Most viral vaccines work by inducing antibodies, which are molecules that prevent pathogens from entering and replicating in cells...
  21. IMMUNOGENETIC MECHANISMS OF VACCINE RESPONSE
    Gregory A Poland; Fiscal Year: 2013
    ..Lastly, our work may provide knowledge important to the development of new viral vaccines - particularly against rubella - by understanding genetic restrictions that prevent protective immune ..
  22. Congenital CMV and CNS Infection Mechanisms of Protective Immunity
    WILLIAM JARVIS BRITT; Fiscal Year: 2013
    ..as an important starting point for our experiments to identify biological molecules such as antibody and/or viral vaccines attenuated in their capacity to infect the brain or cause brain disease that can limit infection and disease ..
  23. Synthetic Viral Genome Design for Rapid Vaccine Development
    Eckard Wimmer; Fiscal Year: 2012
    ..virus should provide a rapid, safe, inexpensive, general and reliable method of creating the raw material for viral vaccines. In principle, vaccines could be created quickly even for very poorly characterized viruses, as long as a ..
  24. How IL-10R blockade can resolve persistent viral infections
    Matthias G Von Herrath; Fiscal Year: 2010
    ..establishing paradigms for synergy in combination therapies with PD-1/PD-1L blockade, antiviral drugs and anti-viral vaccines A direct comparison of persistent versus acute infection with LCMV will form the basis for this investigation...
  25. The Immunogenetics of Measles Immunity
    Gregory A Poland; Fiscal Year: 2013
    ..Lastly, our work may provide knowledge important to the development of new viral vaccines-particularly against measles-by understanding genetic restrictions that prevent protective immune responses to ..
  26. Viral Immunity
    Andrew D Robertson; Fiscal Year: 2010
    ..provides the essential foundation for understanding virus-host interaction and the rational design of anti-viral vaccines and therapies that bolster host anti-viral immunity...
  27. Mechanism of action of codon pair bias
    ALLEN BRUCE FUTCHER; Fiscal Year: 2013
    ..the mechanim by which codon pair bias causes attenuation, and this lack of knowledge is slowing the work with viral vaccines. In this proposal, we will investigate, for the first time, the mechanism of attenuation by bad codon pair ..
  28. CHILDHOOD VACCINES AND DENTAL CARIES IMMUNITY
    Daniel Smith; Fiscal Year: 2007
    ..polysaccharide of Haemophilus influenza b), cellular[unreadable] (Bordetella pertussis), or intact attenuated viral vaccines (poliovirus)[unreadable] administered immediately prior to the critical period of mutans[unreadable] ..
  29. Microcarrier / CEF / Media SYSTEM to make Viral Vaccines
    WILLIAM HILLEGAS; Fiscal Year: 2002
    ..PROPOSED COMMERCIAL APPLICATION: Many animal vital vaccines (e.g. Marek's) and human viral vaccines are produced using chick embryo cells, either in roller bottle systems or in embryonated chicken eggs...
  30. PROSTATE CANCER GENE THERAPY WITH RECOMBINANT VACCINES
    Martin Sanda; Fiscal Year: 1999
    ..These studies aim to provide a framework for the eventual development and clinical application of recombinant viral vaccines targeting human prostatic antigens in the setting of androgen deprivation therapy.
  31. HIV Vaccine Design and Development Team
    PAUL MADDON; Fiscal Year: 2001
    ..antiviral antibody response, we will also examine cellular immune response elicited by both the subunit and viral vaccines to guide our selection of the optimum construct(s) for further development...
  32. IMMUNOGENETIC MECHANISMS OF VACCINE RESPONSE
    Gregory A Poland; Fiscal Year: 2010
    ..Our long-term objective isto determine the genetic mechanisms influencing the immune response to live viral vaccines, and to answer the question of how and to what degree differences in immune responses that depend upon the ..
  33. MECHANISMS OF IMMUNITY TO VIRAL VACCINES IN INFANCY
    Hayley Gans; Fiscal Year: 2004
    DESCRIPTION (Adapted from Applicant's Description): This proposal is to study mechanisms of immunity to viral vaccines in infancy...
  34. A MICROCARRIER/CEF/MEDIA SYSTEM TO MAKE VIRAL VACCINES
    WILLIAM HILLEGAS; Fiscal Year: 2000
    ..This new system we propose, will include CEF cells, microcarriers and the custom media. ..
  35. SIV delta vif DNA Vaccines with Cytokine Adjuvants
    Ellen Sparger; Fiscal Year: 2004
    ..In a novel approach to immunization with live-attenuated viral vaccines, cats were inoculated by the intramuscular route with plasmid DNA containing the FIV-delta vif proviral genome...
  36. HIGHLY ATTENUATED SIV VIF DNA VACCINES
    Ellen Sparger; Fiscal Year: 2001
    ..In a novel approach to immunization with live attenuated viral vaccines; cats were inoculated by the intramuscular route with plasmid DNA containing the FIV-delta vif proviral genome...
  37. Improved influenza A virus vaccines using alpha-Gal epitope modification
    Charles Link; Fiscal Year: 2009
    ..3) We will test the hypothesis that use of Gal containing viral vaccines will enhance the immune response in a preclinical model of immunosenescence...
  38. Transcutaneous Immunization for an Anthrax Vaccine
    Richard Kenney; Fiscal Year: 2003
    ..that this is a safe and efficient method of vaccination for a wide range of vaccines, including inactivated viral vaccines, killed bacteria and multivalent high molecular weight (>800,000 Daltons) subunit vaccines...
  39. SENDAI VIRUS-SPECIFIC T CELL IDIOTOPES
    Hildegund Ertl; Fiscal Year: 1990
    ..These studies should indicate whether anti-idiotypic antibodies have merits as anti-viral vaccines. The use of this type of vaccine would be of great value as monoclonal antibodies can be prepared at low cost ..
  40. Microcarriers designed for protein & sera free media
    WILLIAM HILLEGAS; Fiscal Year: 2004
    ..As manufacturers of viral vaccines and other biologicals move toward completely animal product-free manufacturing conditions, a substrate ..
  41. Microcarriers designed for protein & sera free media
    WILLIAM HILLEGAS; Fiscal Year: 2006
    ..As manufacturers of viral vaccines and other biologicals move toward complete animal product-free manufacturing conditions, a substrate ..
  42. Viruses with Pseudolethal Mutations as Vaccines
    Vladimir Yamshchikov; Fiscal Year: 2004
    We propose a new category of viral vaccines consisting of replication competent viruses with pseudolethal mutations that render them incapable to form the infectious progeny...
  43. SHIV ADAPTATION AND PATHOGENESIS IN MACAQUES
    Paul Luciw; Fiscal Year: 2000
    ..Novel SHIV clones utilizing various co-receptors will be essential for evaluation of anti-viral vaccines and novel anti-viral inhibitors which are aimed at blocking virion entry into cells...
  44. MECHANISMS OF ACTION OF VIRAL & NON-VIRAL ONCOGENES
    William Hayward; Fiscal Year: 1993
    ..6) the immune responses of cats to FeLV infection and FeLV-induced leukemogenesis, and to experimental viral vaccines, (7) the biochemical nature of FeLV- and RD114-specific cell-surface antigens (e.g...
  45. STABILITY AND STRUCTURE OF GP 120 ON INACTIVATED HIV
    Haynes Sheppard; Fiscal Year: 1999
    DESCRIPTION: (Adapted from applicant's abstract): A traditionally successful approach to viral vaccines, the whole inactivated virus (WIV), has received relatively little attention in the overall effort to develop an effective HIV/AIDS ..
  46. Immunostimulatory single cycle SIV Vaccines incorporating TRAF-mediated molecular
    GEOFFREY STONE; Fiscal Year: 2009
    ..Typically, live attenuated viral vaccines for diseases such as influenza utilize the immunostimulatory nature of the virus itself to adjuvant the immune ..
  47. Self-limiting, and Dominant-negative Herpes Simplex Virus Recombinants
    Feng Yao; Fiscal Year: 2007
    ..efficiency in eliciting an effective host immune response are the two major criteria in developing recombinant viral vaccines against wild-type viral infections...
  48. SYNERGISTIC ACTIVITY OF INTERFERON AND ANTIBODY
    Marlyn Langford; Fiscal Year: 1990
    ..These studies will be important in evaluating the immunoprophylactic potential of and development of subunit viral vaccines and determining the potential usefulness of IFN and antibody combinations in treatment of viral infections.
  49. HIV 1 VACCINE AND IMMUNITY STUDY
    Lung Ji Chang; Fiscal Year: 2001
    ..Even through whole viral vaccines have been successfully used for treating various viral diseases, whole-HIV based vaccines have not been tested ..
  50. SPECIFICITY OF THE CTL RESPONSE TO MURINE LEUKEMIA VIRUS
    DAVID FLYER; Fiscal Year: 1992
    ..on viral antigens which stimulate the generation of CTL and serve as CTL- recognition antigens is essential for the manufacture of more effective anti-viral vaccines and for the successful use of CTL in immunotherapeutic protocols.
  51. A Max-Ad Vaccine for Mucosal Immunity to HIV
    Sybille Sauter; Fiscal Year: 2002
    ..New insight into effective anti-viral vaccines has focused attention on eliciting cellular immune responses...
  52. VACCINE FOR CTL IMMUNITY IN HUMAN IMMUNODEFICIENCY VIRUS
    Kenneth Rock; Fiscal Year: 1999
    ..The hypothesis underlying this Aim is that optimal anti-viral vaccines will need to elicit not only CTL responses but also CD4 T cell responses and both systemic and mucosal ..
  53. ANTI-VIRAL IMMUNE MECHANISMS IN EARLY CHILDHOOD
    Ann Arvin; Fiscal Year: 2003
    ..Whereas most viral pathogens are encountered during the first few years of life, and most viral vaccines must be given during this interval in order to provide maximum benefit, very little is known about the ..
  54. Targeted Subcellular Delivery of Oligonucleotides and Proteins
    Kyung Dall Lee; Fiscal Year: 2009
    ..The working delivery carrier will be then tested using viral nucleoproteins for anti-viral vaccines. The optimal vaccine delivery vehicle resulting from this project will be a non-viral/ non-bacterial delivery ..
  55. Pattern Recognition Molecule Mindin As Adjuvant
    You Wen He; Fiscal Year: 2007
    ..this application, we propose to examine whether Mindin can be used as a molecular adjuvant for bacterial and viral vaccines. First, Mindin will be purified and used as an adjuvant in immunizations with influenza virus and group B ..
  56. HUMORAL IMMUNITY AND RESPIRATORY VIRAL INFECTION
    Christopher Coleclough; Fiscal Year: 2002
    ..sets of antigen-transporting cells, by purifying such cells, exposing them to infectious or inactivated viral vaccines, and determining the quality of immunity generated by the cell populations after reinjection into mice...
  57. SIMIAN VACCINE EVALUATION UNITS
    Mark Lewis; Fiscal Year: 2000
    ..strategies investigated will include nucleic acid vaccines, recombinant proteins, whole-killed and attenuated viral vaccines as well as immunologic adjuvants and delivery vehicles...
  58. SIMIAN VACCINE EVALUATION UNITS
    Michael Murphey Corb; Fiscal Year: 1999
    ..strategies investigated will include nucleic acid vaccines, recombinant proteins, whole-killed and attenuated viral vaccines as well as immunologic adjuvants and delivery vehicles...
  59. SIMIAN VACCINE EVALUATION UNITS
    William Morton; Fiscal Year: 1999
    ..strategies investigated will include nucleic acid vaccines, recombinant proteins, whole-killed and attenuated viral vaccines as well as Immunologic adjuvants and delivery vehicles...
  60. MOLECULAR APPROACHES TO HUMAN VIRAL VACCINES
    Ann Arvin; Fiscal Year: 1999
    ..among individuals representing the broad range of disciplines relevant to the development of human viral vaccines. Particular emphasis will be placed on participation by students, postdoctoral fellows and junior ..
  61. Single cycle reporter assay for quantifying HIV-1 Nab
    John Kappes; Fiscal Year: 2003
    ..humoral arm of the immune response is considered to be the major protective mechanism elicited by a variety of viral vaccines. The induction of a potent neutralizing antibody response is one of the principal goals in HIV vaccine ..
  62. BIOCHEMICAL CONTROL OF MICROCARRIER PROCESSES
    WILLIAM HILLEGAS; Fiscal Year: 1990
    ..cell anchorage materials (microcarriers and roller bottles) are in large-scale use in the manufacture of viral vaccines for humans and animals, representing a $5 million market...
  63. MEMORY T CELL INDUCTION IN NEONATES BY VIRAL VACCINES
    Marcella Sarzotti Kelsoe; Fiscal Year: 2000
    ..3) To determine the life-span and the protective effect of memory CTL activated in newborn mice by viral vaccines. 4) To examine the role of CD4+ T cells and antigen in the maintenance of the CTL memory response.
  64. A SCALABLE PHOTOCHEMICAL INACTIVATION PROCESS FOR HIV
    Haynes Sheppard; Fiscal Year: 2001
    A traditionally successful approach to viral vaccines, whole inactivated virus (WIV), has received relatively little attention in the overall effort to develop an effective HIV/AIDS vaccine...
  65. Starburst Viruses: A paradigm for modification of biological surfaces
    Leonard Seymour; Fiscal Year: 2009
    ..g. hepatitis) and inherited diseases (e.g. cystic fibrosis) and notably in development of antibody-resistant viral vaccines suitable for repeated use in diseases such as HIV, malaria, TB and influenza.